CN107922416B - 含有取代的胍基团的咪唑并[4,5-c]环化合物 - Google Patents

含有取代的胍基团的咪唑并[4,5-c]环化合物 Download PDF

Info

Publication number
CN107922416B
CN107922416B CN201680049829.8A CN201680049829A CN107922416B CN 107922416 B CN107922416 B CN 107922416B CN 201680049829 A CN201680049829 A CN 201680049829A CN 107922416 B CN107922416 B CN 107922416B
Authority
CN
China
Prior art keywords
alkyl
compound
hydrogen
salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680049829.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922416A (zh
Inventor
乔治·W·格里斯格拉伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shuwanuo Intellectual Property Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to CN202110672923.1A priority Critical patent/CN113402518B/zh
Publication of CN107922416A publication Critical patent/CN107922416A/zh
Application granted granted Critical
Publication of CN107922416B publication Critical patent/CN107922416B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680049829.8A 2015-08-31 2016-08-26 含有取代的胍基团的咪唑并[4,5-c]环化合物 Active CN107922416B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110672923.1A CN113402518B (zh) 2015-08-31 2016-08-26 含有取代的胍基团的咪唑并[4,5-c]环化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211896P 2015-08-31 2015-08-31
US62/211,896 2015-08-31
PCT/US2016/048831 WO2017040234A1 (en) 2015-08-31 2016-08-26 IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110672923.1A Division CN113402518B (zh) 2015-08-31 2016-08-26 含有取代的胍基团的咪唑并[4,5-c]环化合物

Publications (2)

Publication Number Publication Date
CN107922416A CN107922416A (zh) 2018-04-17
CN107922416B true CN107922416B (zh) 2021-07-02

Family

ID=56853873

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680049829.8A Active CN107922416B (zh) 2015-08-31 2016-08-26 含有取代的胍基团的咪唑并[4,5-c]环化合物
CN202110672923.1A Active CN113402518B (zh) 2015-08-31 2016-08-26 含有取代的胍基团的咪唑并[4,5-c]环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110672923.1A Active CN113402518B (zh) 2015-08-31 2016-08-26 含有取代的胍基团的咪唑并[4,5-c]环化合物

Country Status (5)

Country Link
US (1) US10118925B2 (enExample)
EP (1) EP3344623B1 (enExample)
JP (1) JP6956071B2 (enExample)
CN (2) CN107922416B (enExample)
WO (1) WO2017040234A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040233A1 (en) 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
JP7010286B2 (ja) 2016-08-26 2022-01-26 スリーエム イノベイティブ プロパティズ カンパニー グアニジノ基で置換された縮合［１，２］イミダゾ［４，５－ｃ］環状化合物
EP3589631B1 (en) 2017-03-01 2021-07-21 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing guanidine substituted benzamide groups
US12024514B2 (en) * 2018-11-26 2024-07-02 Solventum Intellectual Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
EP0894797A4 (en) 1997-01-09 2001-08-16 Terumo Corp NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
WO2005018551A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
MY161812A (en) 2003-11-25 2017-05-15 3M Innovative Properties Co Substituted imidazo ring systems and methods
WO2005051380A1 (en) 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r)
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
AU2005283085B2 (en) 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
ES2384390T3 (es) * 2004-09-02 2012-07-04 3M Innovative Properties Company Sistemas cíclicos 1-alcoxi-1H-imidazo y métodos asociados
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006244635A1 (en) 2005-04-01 2006-11-16 Coley Pharmaceutical Group, Inc. Ring closing and related methods and intermediates
CN101309687A (zh) 2005-11-04 2008-11-19 科勒制药集团公司 经羟基和烷氧基取代的1h-咪唑并喹啉及其方法
WO2012024284A1 (en) 2010-08-17 2012-02-23 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2017040233A1 (en) 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Structure-Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues;Nikunj M. Shukla et al.;《J. Med. Chem.》;20100518;第53卷;4450-4465 *

Also Published As

Publication number Publication date
US20180244669A1 (en) 2018-08-30
CN113402518A (zh) 2021-09-17
JP6956071B2 (ja) 2021-10-27
CN107922416A (zh) 2018-04-17
WO2017040234A1 (en) 2017-03-09
JP2018525427A (ja) 2018-09-06
EP3344623A1 (en) 2018-07-11
EP3344623B1 (en) 2021-02-17
US10118925B2 (en) 2018-11-06
CN113402518B (zh) 2023-08-22

Similar Documents

Publication Publication Date Title
US10487081B2 (en) Guanidine substituted imidazo[4,5-c] ring compounds
US10414779B2 (en) Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups
CN107922416B (zh) 含有取代的胍基团的咪唑并[4,5-c]环化合物
US10766896B2 (en) Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups
US11306083B2 (en) Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
CA3034553C (en) Fused [1,2]imidazo[4,5-c] ring compounds substituted with guanidino groups
BR112018004044B1 (pt) Compostos de anel imidazo [4,5-c] substituídos com guanidina, usos e composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240327

Address after: American Minnesota

Patentee after: Shuwanuo Intellectual Property Co.

Country or region after: U.S.A.

Address before: American Minnesota

Patentee before: 3M INNOVATIVE PROPERTIES Co.

Country or region before: U.S.A.

TR01 Transfer of patent right